perphenazine · Schering · NDA 010775, 011213, 011294, 011361, 011557
Trilafon
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 8
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 010775 · 001 · RLD · discontinued | tablet, oral | 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 010775 · 002 · RLD · discontinued | tablet, oral | 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 010775 · 003 · RLD · discontinued | tablet, oral | 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 010775 · 004 · RLD · discontinued | tablet, oral | 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 011213 · 002 · discontinued | injectable, injection | 5MG/ML | open |
| 011294 · 002 · discontinued | syrup, oral | 2MG/5ML | open |
| 011361 · 002 · discontinued | tablet, extended release, oral | 8MG | open |
| 011557 · 001 · discontinued | concentrate, oral | 16MG/5ML | open |